Schroder Investment Management Group Has $21.59 Million Stock Holdings in ResMed Inc. (NYSE:RMD)

Schroder Investment Management Group boosted its position in ResMed Inc. (NYSE:RMD - Free Report) by 59.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 94,088 shares of the medical equipment provider's stock after purchasing an additional 34,924 shares during the quarter. Schroder Investment Management Group owned about 0.06% of ResMed worth $21,593,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. OFI Invest Asset Management bought a new stake in shares of ResMed in the fourth quarter valued at about $39,000. BankPlus Trust Department acquired a new stake in ResMed in the 4th quarter worth about $44,000. Rosenberg Matthew Hamilton acquired a new stake in ResMed in the 4th quarter worth about $54,000. SBI Securities Co. Ltd. bought a new stake in ResMed in the 4th quarter valued at about $67,000. Finally, Kentucky Trust Co acquired a new position in shares of ResMed during the 4th quarter worth approximately $82,000. 54.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. The Goldman Sachs Group started coverage on shares of ResMed in a research report on Thursday, January 16th. They issued a "buy" rating for the company. JPMorgan Chase & Co. lifted their price objective on ResMed from $270.00 to $286.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Needham & Company LLC reissued a "hold" rating on shares of ResMed in a report on Friday, January 31st. Stifel Nicolaus dropped their price target on ResMed from $250.00 to $240.00 and set a "hold" rating for the company in a research note on Wednesday, March 5th. Finally, Citigroup raised shares of ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $249.73.

Insider Activity

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $219.74, for a total value of $439,480.00. Following the completion of the transaction, the director now directly owns 73,218 shares in the company, valued at approximately $16,088,923.32. This represents a 2.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kaushik Ghoshal sold 9,113 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $235.40, for a total transaction of $2,145,200.20. Following the transaction, the insider now directly owns 9,725 shares of the company's stock, valued at $2,289,265. The trade was a 48.38 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,004 shares of company stock valued at $9,618,128. 0.71% of the stock is currently owned by corporate insiders.

ResMed Price Performance

Shares of ResMed stock traded up $7.89 during midday trading on Monday, hitting $213.06. 2,203,316 shares of the company traded hands, compared to its average volume of 1,009,725. The firm's fifty day moving average price is $229.90 and its 200-day moving average price is $236.73. The stock has a market cap of $31.29 billion, a price-to-earnings ratio of 25.15, a PEG ratio of 1.53 and a beta of 0.75. ResMed Inc. has a 12 month low of $172.19 and a 12 month high of $263.05. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33.

ResMed (NYSE:RMD - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. As a group, sell-side analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th were given a $0.53 dividend. The ex-dividend date was Thursday, February 13th. This represents a $2.12 annualized dividend and a yield of 1.00%. ResMed's dividend payout ratio is presently 25.03%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.